Sparsentan approved to treat adult patients with primary immunoglobulin A nephropathy (IgAN)

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sparsentan (Filspari) to treat primary immunoglobulin A nephropathy (IgAN).